Tramadol Versus Celecoxib for Reducing Pain in Outpatient Hysteroscopy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

210 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2014-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the effectiveness of Tramadol and Celecoxib in reducing pain during outpatient hysteroscopy. Women undergoing outpatient hysteroscopy in Cairo university will be divided into 3 groups, the first group will receive Tramadol 100 1 hour before the procedure, the second group will receive Celecoxib 200mg 1 hour before the procedure and the third will receive a placebo. Pain will be assessed by a visual analogue scale.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tramadol Versus Celecoxib for Reducing Pain During Operative Office Hysteroscopy

NCT02736071

Hysteroscopy

UNKNOWN PHASE3

Tramadol Versus Celecoxib for Reducing Pain During Office Hysteroscopy in Post Menopausal Women

NCT02736019

Hysteroscopy

UNKNOWN PHASE3

Evaluation of the Role of Tramadol 50mg as an Analgesic During Outpatient Hysteroscopy

NCT02068209

Pain

COMPLETED PHASE2

Tramadol Versus Diclofenac for Reducing Pain Before Outpatient Hysteroscopy

NCT02419651

Pain, Post Procedural Pain, Procedural

UNKNOWN PHASE3

Tramadol Versus Diclofenac for Prevention of Pain in Operative Outpatient Hysteroscopy

NCT02428777

Pain

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hysteroscopic examination is currently the most informative investigation for patients with abnormal uterine bleeding and infertility. Outpatient hysteroscopy involves the use of miniaturized endoscopic equipment to directly visualise the endometrial cavity, without the need of formal theatre facilities, general or regional anaesthesia.

Outpatient hysteroscopy is increasingly being used as a cost-effective alternative to in-patient hysteroscopy under general anaesthesia. Like other outpatient gynaecological procedures, however, it has the potential to cause pain severe enough for the procedure to be abandoned.

Several drugs have been used to reduce pain during the procedure. Celecoxib is a highly selective Cyclooxygenase-2 inhibitor (COX-2 inhibitor) whereas other Non-steroidal anti-inflammatory drugs (NSAIDS) like Ibuprofen, Diclofenac, and Naproxen inhibit both COX-1 and COX-2. COX-1 is the only isoenzyme found in platelets, and plays a role in the protection of the gastrointestinal mucosa, renal hemodynamics, and platelet thrombogenesis. In theory, this selectivity allows celecoxib and other COX-2 inhibitors to reduce inflammation and pain while minimizing gastrointestinal adverse drug reactions. COX-1 is involved in synthesis of prostaglandins and thromboxane, but COX-2 is only involved in the synthesis of prostaglandin. Therefore, inhibition of COX-2 inhibits only prostaglandin synthesis without affecting thromboxane, so offers no cardioprotective effects of nonselective NSAIDs .

Opioid analgesics are widely used for the control of moderate to severe pain. Tramadol hydrochloride, a synthetic opioid is an orally active, clinically effective centrally acting analgesic having a lower incidence of respiratory depression, cardiac depression, side effects on smooth muscle and abuse potential as compared to typical opioid agents.

The study will be conducted in the outpatient hysteroscopy clinic in Cairo university hospitals. All patients attending the outpatient hysteroscopy clinic will be invited to participate in the study. The invitation will include a clear full explanation of the study and patients will provide oral consent. Written informed consent is not needed since the procedure and intervention carries almost no risk to the patient and the patient will not receive anesthesia and will be fully conscious. Only patients consenting verbally to participate will be included in the trial.

Tramadol, celecoxib and placebo will be enclosed in sealed envelopes which will be numbered using computer generated random table. Neither the patient nor the physician will be aware of the drug used. 210 women will be categorized into 3 groups: Group I who will receive Tramadol 100mg (Trama SR®, Global Napi) orally 1 hour before the procedure, group II who will receive Celecoxib 200mg (Celebrex® 200, Pfizer) 1 hour before the procedure, and group III who will receive placebo acting as the control group.

Full history will be taken followed by general and local examination. The procedure will be done in the lithotomy position. Hysteroscopy will be done using a 5mm outer diameter continuous flow hysteroscope with a French working channel and a 30 degrees direction of view provided by Techno GmbH and CO. The hysteroscope will be introduced using the vaginoscopy technique, in which no speculum will be used. The cervix will be detected and the external os will be identified using the hysteroscope. The hysteroscope will be introduced in the uterine cavity. Saline will be used as the distension medium and the pressure will be set at 100mm Hg. The anterior wall, posterior wall and tubal ostea will be visualized, any polyps, adhesions septa, congenital malformations or submucous fibroids will be noted.

Base line characteristics and perception of pain will be compared.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tramadol

Women will receive Tramadol 100mg 1 hour before the procedure.

Group Type ACTIVE_COMPARATOR

Tramadol

Intervention Type DRUG

Tramadol 100mg will be given to 70 women before the procedure.

Celecoxib

Women will receive Celecoxib 200mg 1 hour before the procedure.

Group Type ACTIVE_COMPARATOR

Celecoxib

Intervention Type DRUG

Celecoxib 200mg will be given to 70 women before the procedure.

Placebo

Women will receive a placebo 1 hour before the procedure.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

A placebo will be given to 70 women before the procedure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tramadol

Tramadol 100mg will be given to 70 women before the procedure.

Intervention Type DRUG

Celecoxib

Celecoxib 200mg will be given to 70 women before the procedure.

Intervention Type DRUG

Placebo

A placebo will be given to 70 women before the procedure.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women referred to the outpatient hysteroscopy in Cairo university hospitals
* Consent to the procedure

Exclusion Criteria

* Premenstrual patients
* Patients with missed periods
* Known cardiac disease
* Known gastritis or peptic ulcer
* Known allergy to Tramadol or Celecoxib

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No